Newswise — Leaders from the worlds of science, industry, law and government will converge on the campus of the Ohio State University Medical Center on Monday, Dec. 4, for a symposium designed to explore opportunities for university-industry collaboration and to showcase emerging biomedical technologies in search of commercial partnerships.
The day-long event will be held in the OSU Medical Center's new, $160 million Biomedical Research Tower and will include presentations from Dr. Fred Sanfilippo, senior vice president and executive dean for health sciences and CEO of the OSU Medical Center, and nearly two dozen scientific leaders in the areas of cancer and heart research, drug discovery and development, neurosciences and bioinformatics.
The program also includes a "technology marketplace" where corporate, angel and venture investors can take the first steps toward meeting directly with the inventors behind some of the Medical Center's most innovative and recent products and discoveries. Potential investors will learn how to work with Ohio State's Technology Licensing and Commercialization team and the Office of Business and Industry Contracts to further commercial interests.
The symposium will offer research and collaboration seminars featuring leaders from some of America's leading biotech, pharmaceutical, bioinformatics and medical device companies and dynamic, fast-growing start-ups. Specific session topics include:
* Emerging Trends in Bio-therapeutics Research: Opportunities for Industry and Academic Collaboration * Accelerating Drug Discovery and Development: Experience and Strategies for Improving the Probability of Success * Leveraging Information Technology and Pharmacogenomics to Develop Personalized Medicine * Building Networks for Regional Collaboration in Life Science Research and Development * Gap Funding of Early-Stage Clinical Trials and University Start-ups: Angel Investors, Venture Capital and NIH SBIR/STTR Options
Attendees will also be able to tour the new Biomedical Research Tower, a 10-story, 403,000-square-foot building that doubles the amount of biomedical research space on the Ohio State campus. The building is specifically designed to quicken the pace of discovery and enhance collaboration among the 800 employees who will be housed there. Faculty and staff from multiple programs, including cancer, heart and lung disease, neurobiology, imaging, microbial pathogenesis, pharmacogenomics, bioinformatics, diabetes, structural biology and tissue engineering will begin moving into their new offices and laboratories on a staggered basis following the building dedication Nov. 3.
Sponsors of the symposium include Battelle; Genentech; Chemical Abstracts Service; Porter Wright Morris & Arthur; Thompson Hine LLP; Novartis Pharmaceuticals; BioImagene; Schottenstien Zox & Dunn; Omeris; Eli Lilly; and Cisco Systems.
For symposium information, call Dr. Henry Zheng, director for technology commercialization and partnerships, at 614-293-9022, e-mail him at [email protected], or visit the symposium Web site at: http://medicine.osu.edu/tcp/index.cfm/
The Ohio State University's academic medical center includes the College of Medicine, OSU Physicians and the OSU Health System, comprising University Hospital, James Cancer Hospital, University Hospital East, OSU Harding Hospital, Dodd Hall Rehabilitation Hospital, Ross Heart Hospital and a network of community care sites. OSU Physicians, the practice plan of the OSU Medical Center, is composed of more than 700 regular faculty in the College of Medicine who provide high-quality and coordinated health care to Medical Center patients.
The Ohio State University Medical Center has consistently been named one of America's best hospitals by U.S. News & World Report magazine, with nine specialty programs listed among the country's best in the most recent edition. Also, 173 faculty members are included in the most recent edition of the nationally acclaimed directory "Best Doctors in America."
RSS